We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current RVNC market cap is 383.42M. The company's latest EPS is USD -3.0885 and P/E is -1.19.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 56.78M | 69.8M | 51.94M | 65.39M | 59.88M |
| Operating Income | -139.29M | -53.95M | -46.83M | -34.52M | -32.26M |
| Net Income | -141.18M | -55.7M | -53.15M | -37.47M | -38.12M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 413k | 15.33M | 77.8M | 132.57M | 234.04M |
| Operating Income | -164.46M | -273.16M | -274.68M | -341.96M | -316.78M |
| Net Income | -159.43M | -282.09M | -281.31M | -356.42M | -323.99M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 532.49M | 478.45M | 508.12M | 494.8M | 461.56M |
| Total Liabilities | 638.69M | 630.06M | 606.79M | 624.54M | 624.59M |
| Total Equity | -106.2M | -151.6M | -98.67M | -129.74M | -163.03M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 340.29M | 720.22M | 531.16M | 581.9M | 478.45M |
| Total Liabilities | 114.8M | 345.93M | 462.69M | 569.3M | 630.06M |
| Total Equity | 225.49M | 374.29M | 68.47M | 12.6M | -151.6M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -173.84M | -216.58M | -65.94M | -107.07M | -148.16M |
| Investing | 107.37M | 109.74M | -31.71M | -38.6M | -15.31M |
| Financing | 138.2M | 136.57M | 92.83M | 89.41M | 83.33M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -106.16M | -178.5M | -221.54M | -193.55M | -216.58M |
| Investing | -17.59M | 12.13M | -29.67M | -138.8M | 109.74M |
| Financing | 221.66M | 331.48M | 29.87M | 331.69M | 136.57M |
| Market Cap | 383.42M |
| Price to Earnings Ratio | -1.19 |
| Price to Sales Ratio | 1.65 |
| Price to Cash Ratio | 2.8 |
| Price to Book Ratio | -2.54 |
| Dividend Yield | - |
| Shares Outstanding | 104.9M |
| Average Volume (1 week) | 4.53M |
| Average Volume (1 Month) | 3.25M |
| 52 Week Change | -36.10% |
| 52 Week High | 7.56 |
| 52 Week Low | 2.30 |
| Spread (Intraday) | 0.01 (0.27%) |
| Company Name | Revance Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.revance.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
